Association between adiponectin and metabolic syndrome in older adults from major cities of China

Biomedical and Environmental Sciences

Volumn 23, Issue 1, 2010, Pages 53-61

  Zhuo, Qin ^a   Wang, Zhi Qing ^b   Fu, Ping ^a   Piao, Jian Hua ^a   Yuan, Tian ^a   Xu, Jie ^a   Yang, Xiao Guang ^a,b  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adiponectin; Chinese older adults; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

EID: 77952149903     PISSN: 08953988     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-3988(10)60032-3     Document Type: Article

References (44)

1. Eckel R H, Grundy S M, Zimmet P Z (2005). The metabolic syndrome. Lancet 365, 1415-1428.
2. 2. Cameron A J, Shaw J E, Zimmet P Z (2004). The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 33, 351-375. (Pubitemid 38680634)
3. Grundy S M, Cleeman J I, Daniels S R, et al. (2006). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 21, 1-6.
4. 4. Weyer C, Funahashi T, Tanaka S, et al. (2001). Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86, 1930-1935. (Pubitemid 32472900)
5. 5. Hotta K, Funahashi T, Bodkin N L, et al. (2001). Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50, 1126-1133. (Pubitemid 32374544)
6. 6. Berg A H, Combs T P, Du X, et al. (2001). The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7, 947-953. (Pubitemid 32756433)
7. 7. Lindsay R S, Funahashi T, Hanson R L, et al. (2002). Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360, 57-58. (Pubitemid 34756495)
8. 8. Spranger J, Kroke A, Mohlig M, et al. (2003). Adiponectin and protection against type 2 diabetes mellitus. Lancet 361, 226-228. (Pubitemid 36126226)
9. 9. Snehalatha C, Mukesh B, Simon M, et al. (2003). Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. Diabetes Care 26, 3226-3229. (Pubitemid 37466879)
10. 10. Duncan B B, Schmidt M I, Pankow J S, et al. (2004). Adiponectin and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes 53, 2473-2478. (Pubitemid 39145606)
11. Chan D C, Watts G F, Ng T W, et al. (2005). Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich apoprotein metabolism in overweight men. Clin Biochem 38, 806-812.
12. Farvid M S, Ng T W, Chan D C, et al. (2005). Association of adiponectin and resistiu with adipose tissue compartments, insulin resistance and dyslipidaemia. Diabetes Obes Metab 7, 406-413.
13. 13.Imatoh T, Miyazaki M, Momose Y, et al. (2008). Adiponectin levels associated with the development of hypertension: a prospective study. Hypertens Res 31, 229-233. (Pubitemid 351461101)
14. Chow W S, Cheung B M, Tso A W, et al. (2007). Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 49, 1455-1461.
15. 15.Kumada M, Kihara S, Sumitsuji S, et al. (2003). Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vase Biol 23, 85-89. (Pubitemid 36091630)
16. 16.Tschritter O, Fritsche A, Thamer C, et al. (2003). Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52, 239-243. (Pubitemid 36173174)
17. 17. Pischon T, Girman C J, Hotamishgil G S, et al. (2004). Plasma adiponectin levels and risk of myocardial infarction in men. Jama 291, 1730-1737. (Pubitemid 38489895)
18. 18.Hung J, McQuillan B M, Thompson P L, et al. (2008). Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes 32, 772-779. (Pubitemid 351670618)
19. 19.Lara-Castro C, Fu Y, Chung B H, Garvey W T (2007). Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 18, 263-270. (Pubitemid 46743049)
20. 20. Wang J, Li H, Franco O H, et al. (2008). Adiponectin and metabolic syndrome in middle-aged and elderly Chinese. Obesity 16, 172-178. (Pubitemid 351271968)
21. 21.Azizi F, Salehi P, Etemadi A, et al. (2003). Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pracl 61, 29-37. (Pubitemid 36808841)
22. Pannier B, Thomas F, Eschwege E, et al. (2006). Cardiovascular risk markers associated with the metabolic syndrome in a large French population: The SYMFONIE study. Diabetes Metab 32, 467-474.
23. Gu D, Reynolds K, Wu X, et al. (2005). Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365, 1398-1405.
24. Li L M, Rao K Q, Kong L Z, et al. (2005). A description on the Chinese national nutrition and health survey in 2002. Chinese Journal of Epidemiology 26, 478-484. (In Chinese)
25. World Health Organization (1999). Diabetes and non communicable disease risk factor surveys - a field guide. World Health Organization, Geneva.
26. Alberti K G, Zimmet P, Shaw J (2005). The metabolic syndrome-a new worldwide definition. Lancet 366, 1059-1062.
27. Chobanian A V, Bakris G L, Black H R, et al. (2003). Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252.
28. American Diabetes Association (2004). Diagnosis and classification of diabetes mellitus. Diabetes care 27 Suppl 1, S5-S10.
29. StataCorp (2007). Stata Statistical Software: Release 10. College Station, TX: StataCorp LP.
30. Cnop M, Havel P J, Utzschneider K M, et al. (2003). Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46, 459-469.
31. Arita Y, Kihara S, Ouchi N, et al. (1999). Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257, 79-83.
32. Adamczak M, Rzepka E, Chudek J, et al. (2005). Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol 62, 114-118.
33. 33.Liu J, Young T K, Zinman B, et al. (2006). Lifestyle variables, non-traditional cardiovascular risk factors, and the metabolic syndrome in an Aboriginal Canadian population. Obesity 14, 500-508. (Pubitemid 46219770)
34. Chen C C, Li T C, Chang P C, et al. (2008). Association among cigarette smoking, metabolic syndrome, and its individual components: The metabolic syndrome study in Taiwan. Metabolism 57, 544-548.
35. 35.Baik I, Shin C (2008). Prospective study of alcohol consumption and metabolic syndrome. Am J Clin Nutr 87, 1455-1463. (Pubitemid 351679790)
36. 36.Lac G, Cavalie H, Ebal E, Michaux O (2008). Effects of a high fat diet on bone of growing rats. Correlations between visceral fat, adiponectin and bone mass density. Lipids Health Dis 7, 16. (Pubitemid 351712945)
37. 37.Yannakoulia M, Yiannakouris N, Bluher S, et al. (2003). Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 88, 1730-1736. (Pubitemid 36623396)
38. 38.Hanley A J, Karter A J, Festa A, et al. (2002). Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. Diabetes 51, 2642-2647. (Pubitemid 34827418)
39. 39.Lann D, LeRoith D. (2007). Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am 91, 1063-1077. (Pubitemid 47625441)
40. 40.Penno G, Miccoli R, Pucci L, et al. (2006). The metabolic syndrome. Beyond the insulin resistance syndrome. Pharmacol Res 53, 457-468. (Pubitemid 44236092)
41. 41. Janssen I, Katzmarzyk P T, Ross R (2004). Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 79, 379-384. (Pubitemid 41115579)
42. Bray G A. (2004). Medical consequences of obesity. J Clin Endocrinol Metab 89, 2583-2589.
43. Kern P A, Di Gregorio G B, et al. (2003). Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 52, 1779-1785.
44. 44. Seino Y, Hirose H, Saito I, et al. (2007). High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. Metabolism 56, 1493-1499. (Pubitemid 47562499)